OncoSil Medical Limited (ASX:OSL)
Australia · Delayed Price · Currency is AUD 1.500
+0.010 (0.67%)
Oct 29, 2025, 1:52 PM AEST
OncoSil Medical Company Description
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma.
The company’s lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy.
OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.
OncoSil Medical Limited
| Country | Australia |
| Founded | 2005 |
| Industry | Medical Devices |
| Sector | Healthcare |
| CEO | Nigel Lange |
Contact Details
Address: 7 Eden Park Drive Macquarie Park, 2113 Australia | |
| Phone | 61 2 8935 9629 |
| Website | oncosil.com |
Stock Details
| Ticker Symbol | OSL |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000OSL3 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Nigel Lange | Chief Executive Officer, MD and Director |
| Shelley Steyn | Chief Financial Officer |
| David Turner | Head of Medical Affairs |
| David Wood | Joint Company Secretary |
| Timothy Luscombe B.Com., C.A. | Joint Company Secretary |